Company news

Cingulate Inc. (NASDAQ:CING) news

Cingulate Inc. news releases on 6ix. Latest, Sep 17, 2026: Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital…

Cingulate Inc. (NASDAQ:CING) news

Press releases & updates

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate Provides Management Team Update

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD

FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate Announces Adjournment of Special Meeting

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD